

Prognostic risk profiling for breast cancer


→ AI testing from routine H&E to help oncologists select the best treatment plan for their patients

Pathology-based risk profiling makes precision testing more accessible



Indication

Adults with primary invasive early breast cancer (ER+/HER2-).




Multimodal AI

Combines image analysis and patient clinical information.




PDF report

Easily accessible and supports pathologist interpretation.



Workflow agnostic

Deployment is feasible across existing IMS systems or IT settings.



Impact

Clinical studies show RlapsRisk[®] BC more precisely stratifies patients into high and low risk groups than traditional and current assessment methods.¹

RlapsRisk[®] BC shows potential to help clinicians reduce overtreatment and better identify high-risk patients who could benefit from adjuvant chemotherapy or precision therapies.¹

Clinical context

Risk of relapse significantly impacts ER+/HER2- breast cancer prognosis, informing eligibility for more aggressive treatments, like CDK4/6 inhibitors, or allowing safe avoidance of unnecessary chemotherapy.

Meeting pathologists where they are to deliver results where they're needed



Slide preparation

Prepare slides from resected tissue. Select the best slide.



AI image analysis

RlapsRisk BC analyzes the WSI and gives a risk score.



Report delivery

RlapsRisk BC provides a PDF indicating "high risk" or "low risk," to support treatment decision making.

Digitization

Convert the slide into a whole slide image (WSI).



Input clinical pathological values

Via a web app, enter key patient data which is combined with the AI score.



Established in Clinical Utility

Informed by international breast oncology and pathology experts, RlapsRisk BC and previous prototypes have been tested in various international lab settings for 3+ years.



The device is currently under development, and not for clinical use. Not FDA cleared or approved for use in USA. Please contact Owkin for more information. Images shown may represent the range of products, or be for illustration purposes only, and may not be an exact representation of the product.

RlapsRisk BC is developed within the PortrAlt consortium, a french consortium financed by the government within the framework of France 2030 and by the European Union - Next Generation EU within the framework of the France Relance Plan.

Manufacturer: Owkin France. RlapsRisk® is a trademark of Owkin Inc. European Patent Application No. EP21306284.7 / International Application No. PCT/US2022/043692

Get in touch with us at owkin.com/contact

© 2025 Owkin, Inc | Public information | Ref. 006V9 | 9 October 2025

